<DOC>
	<DOCNO>NCT00063960</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy floxuridine irinotecan use different way stop tumor cell divide stop grow die . Hepatic arterial infusion use catheter deliver chemotherapy directly liver . Combining one drug give different way may kill tumor cell remain surgery . PURPOSE : Phase II trial study effectiveness systemic irinotecan hepatic arterial infusion floxuridine surgery treat patient hepatic ( liver ) metastases colorectal cancer .</brief_summary>
	<brief_title>Hepatic Arterial Infusion With Floxuridine Systemic Irinotecan After Surgery Treating Patients With Hepatic ( Liver ) Metastases From Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity hepatic arterial infusion floxuridine systemic irinotecan adjuvant liver metastases resection ablation without resection patient hepatic metastasis secondary colorectal cancer . - Determine overall survival patient treat regimen . - Determine time hepatic recurrence progression patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord prior therapy ( liver metastasis resection v ablation without resection ) . Within 4-8 week prior resection ablation , patient receive hepatic arterial infusion floxuridine continuously day 1-14 irinotecan IV 30 minute day 1 15 . Treatment repeat every 28 day 6 course absence unacceptable toxicity . Patients follow every 3 month 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic colorectal adenocarcinoma Primary colorectal adenocarcinoma completely resect ( R0 disease ) No evidence residual , viable tumor abdominal/pelvic helical CT scan MRI IV contrast Metastatic disease No 9 liver metastasis All lesion completely resect completely treat ablation ( without resection ) All lesion treat ablation must less 5 cm size least 5 mm away main/left/right portal vein , common bile duct , inferior vena cava All resect lesion must negative surgical margin ( R0 ) Disease progression prior systemic irinotecan metastatic disease allow No extrahepatic metastasis confirm chest CT scan except colorectal mesenteric lymph node metastasis resect time primary tumor resection No prior resection extrahepatic metastasis Must entire liver remnant perfuse single catheter Must nuclear medicine macroaggregated albumin flow scan confirm area pump perfusion study registration PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Zubrod 02 Life expectancy Not specify Hematopoietic WBC least 3,000/mm^3 Absolute granulocyte count least 1,500/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2 mg/dL Alkaline phosphatase great 2.0 time upper limit normal ( ULN ) AST ALT great 2.0 time ULN No active hepatitis B C infection No histological evidence cirrhosis Renal Creatinine great 1.5 time ULN Calcium less 1.3 time ULN Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Postmenopausal woman must amenorrheic least 12 consecutive month deem fertile Medically fit begin chemotherapy 4 8 week surgery Prior cancer allow follow criterion meet : Undergone potentially curative therapy prior malignancy No malignancy within past 5 year except follow : Effectively treat basal cell squamous cell skin cancer Carcinoma situ cervix effectively treat surgery alone Lobular carcinoma situ ipsilateral contralateral breast treat surgery alone No evidence recurrence prior malignancy No prior hepatic arterial infusion pump malfunction , malperfusion , infection PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunologic biologic therapy Chemotherapy No prior chemotherapy within 4 week hepatic resection hepatic ablation ( without resection ) No prior hepatic arterial infusion fluorouracil floxuridine Radiotherapy No concurrent adjuvant radiotherapy pelvis No concurrent radiotherapy Other No concurrent systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>